Borrelia burgdorferi, one of the bacteria species causing Lyme disease, has a small genome and is therefore highly dependent on its hosts to obtain many necessary metabolites. Its small genome makes B. burgdorferi an attractive candidate for developing narrow-spectrum antibiotics targeting those essential genes. The use of narrow-spectrum antibiotics may reduce the risk of side effects and the spread of antimicrobial resistances compared with traditional, long-term antibiotic treatments.